Mirikizumab ELISA Kit

• Background:

  Mirikizumab (Eli Lilly and Company), Risankizumab (Boehringer Ingelheim and AbbVie), Tildrakizumab (Sun Pharma), Brazikumab (AstraZeneca), and Guselkumab (Janssen Biotech Inc.) are other drugs which target IL-23 and received the FDA approval for the treatment of psoriasis.

• Product Name Alternative:

  LY-3074828, CAS: 1884201-71-1

• Detection Method:

  Colorimetric

• Assay Type:

  Quantitative

• Sample Type:

  Plasma, Serum

• Detection Range:

  0.31-5 μg/mL

• Recovery:

  80-120 %

• Sensitivity:

  0.156 μg/ml

• Shipping Conditions:

  2-8 °C

• Storage Conditions:

  The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.